Abstract: The present invention discloses a liposomal delivery vehicle that includes lignite extract (or humic or fulvic acid) as a complexing agent to improve the stability and ultradeformability of the liposomal vehicle, thereby improving bioavailability. An emulsion delivery vehicle that includes lignite extract (or humic or fulvic acid) as the complexing agent is also disclosed. These improved delivery vehicles enhance the pharmacokinetic profiles of the active ingredients and reduce the quantities needs for therapeutic effect.
Abstract: Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 18, 2019
Inventors:
Ghaleb Husseini, Mohammad Al-Sayah, Amal Elsadig
Abstract: The present invention relates to lipoproteins containing platinum complex. The invention also relates to a kit comprising said lipoproteins. In particular, the present invention relates to the use of said platinum-complex-bearing lipoproteins for the specific targeting of macrophages and tumour cells in the treatment of cancer.
Type:
Application
Filed:
May 29, 2017
Publication date:
April 18, 2019
Inventors:
Frédéric LIRUSSI, Carmen GARRIDO-FLEURY, Laurent LAGROST
Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
Type:
Application
Filed:
September 10, 2018
Publication date:
April 18, 2019
Inventors:
Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
Abstract: The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 18, 2019
Applicant:
Grünenthal GmbH
Inventors:
Carmen Stomberg, Harald Paul, Klaus Wening, Sebastian Schwier
Abstract: The present invention provides pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances with reduced Ostwald ripening.
Type:
Application
Filed:
September 12, 2018
Publication date:
April 18, 2019
Inventors:
Raj Selvaraj, Chandra U. Singh, David L. Woody
Abstract: Present invention discloses the stable pharmaceutical composition comprising premix of dapagliflozin with at least one pharmaceutically acceptable excipient(s) and process for preparation thereof. Dapagliflozin is highly hygroscopic and hence it is difficult to formulate dapagliflozin as stable pharmaceutical composition. Present invention discloses the stable pharmaceutical composition of dapagliflozin comprising premix of dapagliflozin with lactose.
Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition
Type:
Application
Filed:
October 12, 2017
Publication date:
April 18, 2019
Inventors:
Agnes FERNANDEZ PENA, Onne Peter Hilbert BACKERS, Jose VELADA CALZADA
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Application
Filed:
October 17, 2018
Publication date:
April 18, 2019
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: The invention relates to an oral administration form which comprises at least one species of probiotic microorganisms, where it itself and/or the probiotic bacteria is/are provided with a coating which comprises at least two cellulose ethers.
Type:
Application
Filed:
November 16, 2018
Publication date:
April 18, 2019
Applicant:
Merck Patent GmbH
Inventors:
Markus RUDOLPH, Stefan HENKE, Iris MANNECK
Abstract: An object of the present invention is to provide a particulate composition for an easy-to-take solid preparation, which has excellent moldability (hardness) and slipperiness. The present invention relates to a particulate composition for an easy-to-take solid preparation, comprising sugar alcohol and a gelling agent that will show slipperiness when it is brought into contact with water, wherein a part or whole of the surface of the particulate composition is coated with the gelling agent, to an easy-to-take solid preparation comprising the particulate composition, and to a method for the production of the easy-to-take solid preparation.
Abstract: An artificial device, method and system are provided for the manufacture and use of artificial nanospheres, enclosed resins, and similar technologies for sequestering lipophilic molecules from environments, such as a gastrointestinal tract.
Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 18, 2019
Applicants:
Board of Regents of the University of Texas System, The Ohio State University Research Foundation
Inventors:
Mauro Ferrari, Ennio Tasciotti, Jason Sakamoto
Abstract: A delivery system that allows for targeted released of therapeutics in selected regions of the GI tract is provided. The delivery system is adapted to deliver a certain type of therapeutic, such as a protein-based therapeutic, to a certain area of the GI tract, such the colon of a subject. The delivery vehicle comprises a microbead coated with layers that include: a subcoat layer and a therapeutic agent layer. The delivery vehicles may also include an enteric coating layer and/or a sustained release layer.
Type:
Application
Filed:
March 30, 2017
Publication date:
April 18, 2019
Applicant:
University of Maryland, Baltimore
Inventors:
Hanping FENG, Hua YU, Stephen HOAG, Bowen JIANG
Abstract: The invention relates to a nanoparticle comprising: (i) between 60 wt.-% and 99 wt.-% sorbitan ester, relative to the total weight of the nanoparticle; (ii) a positively charged substance; and (iii) a miRNA. The invention also relates to the methods for producing same and to the uses thereof, particularly for therapeutic uses, such as cancer treatment.
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Type:
Application
Filed:
December 20, 2018
Publication date:
April 18, 2019
Inventors:
Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
Type:
Application
Filed:
September 7, 2018
Publication date:
April 18, 2019
Applicant:
Pfizer Inc.
Inventors:
Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Yong-ho Song, Hong Wang
Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
Abstract: A method of preserving the one or more chemical and/or biological species in a polymer matrix comprising pullulan and trehalose is described. The method includes combining the one or more chemical and/or biological species, an aqueous pullulan and a trehalose solution and drying the resultant mixture to provide a solid polymeric matrix. A polymeric matrix comprising one or more chemical and/or biological species and its use, for example, on surfaces for food preparation, for food preservation and in biological preparations is also described.
Type:
Application
Filed:
October 16, 2018
Publication date:
April 18, 2019
Applicant:
McMaster University
Inventors:
Vincent Ho Yin Leung, Sana Jahanshahi- Anbuhi, Carlos Filipe, M. Monsur Ali
Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.
Abstract: There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.
Type:
Application
Filed:
April 10, 2017
Publication date:
April 18, 2019
Inventors:
Nils Ove Gustafsson, Hans Martensson, Niklas Bergh, Jonas Faijerson Saljo, Sverker Jem
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
Type:
Application
Filed:
December 6, 2018
Publication date:
April 18, 2019
Applicant:
Osmotica Kereskedelmi ES Szolgaltato KFT
Inventors:
Glenn A. MEYER, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Abstract: A superior dual ACE/NEP inhibitor is a combination that selectively targets the ACE C-domain in addition to inhibiting NEP. Such a dual ACE C-domain/NEP inhibitor can be used in the treatment of diverse cardiovascular diseases, including hypertension and heart failure.
Abstract: A composition of chlorogenic acids and method of its use and manufacture in the treatment of metabolic disorders. The composition can be obtained from sunflower seed extract, including Helianthus annulus seeds.
Abstract: Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.
Type:
Application
Filed:
August 23, 2018
Publication date:
April 18, 2019
Applicant:
The Regents of the University of California
Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.
Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
Abstract: Methods for the preparation of nanosized nutrient formulations for enhanced absorption of nutritional agents. The methods include the complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps.
Type:
Application
Filed:
April 16, 2018
Publication date:
April 18, 2019
Applicant:
NSE Products, Inc.
Inventors:
Mark Bartlett, Angela Mastaloudis, Carsten Smitdt, Stephen J. Poole
Abstract: The present invention disclosed a formulation in the form of self-emulsifying drug delivery formulation for improved delivery of tocotrienols comprising a fat-soluble compound, at least one emulsifier, and an oil carrier. The formulation shows an improved bioavailability of tocotrienols.
Type:
Application
Filed:
November 30, 2018
Publication date:
April 18, 2019
Inventors:
Chee Wai FONG, Yee Wei UNG, Jordan Todorov PETKOV
Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
Abstract: Uses of acyl-homoserine lactone compounds are described. In particular, uses of acyl-homoserine lactone compounds as anti-thrombotic agents, to inhibit platelets from becoming hypersensitive, and/or to prevent thrombosis, are described.
Type:
Application
Filed:
December 12, 2018
Publication date:
April 18, 2019
Applicant:
The University of Toledo
Inventors:
Randall G. Worth, Glenn R. Westphal, Brenton R. Keeley, Leah M. Wuescher
Abstract: A method of treating post-traumatic stress disorder is provided. The method includes administering a composition of amino acids, melatonin, and vitamins, and then tracking, through testing and the like, a progression of the treatment. Typically, but not necessarily, the composition is administered orally in the form of pills, powder, pre-mixed food items, and the like.
Abstract: Multi-functions Selective COX inhibitors The invention relates to a new class of compounds targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeting COX-1 or detection of COX-1 in relating disorders or diseases such as cancer and neuroinflammation, in particular in neurological (e.g. autism spectrum disorders) and neurodegenerative diseases (e.g. Alzheimer's diseases, Parkinson's diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), HIV dementia and prion diseases), and in gynecological tumour (e.g. ovarian cancer), neck and head tumor, and haematological tumours (e.g. multiple myeloma) and in the detection of COX-1 in “in vitro” (cells and tissues) and in “in vivo”.
Type:
Application
Filed:
April 26, 2017
Publication date:
April 18, 2019
Inventors:
Antonio SCILIMATI, Maria Grazia PERRONE, Paola VITALE
Abstract: An object of the present invention is to provide a novel anti-Tritrichomonas agent. Provided is an anti-Tritrichomonas agent containing luliconazole.
Abstract: A composition for controlling or preventing microsporidia in a fish or a seafood is prepared by using, as an active ingredient, at least one compound selected from the group consisting of compounds represented by the following chemical formula (I): (wherein, R2, R4, R5, R6 and R7 each independently represent a specific substituent), pharmaceutically acceptable salts thereof, and compounds generating the compounds represented by the chemical formula (I) by metabolism in the body of the fish or the seafood. By using this composition for controlling or preventing microsporidia in a fish to or a seafood, a method for controlling or preventing microsporidia in a fish or a seafood is provided, which prevents microsporidian infection in the muscle or organs of the fish or the seafood, and/or suppresses the growth of microsporidia in the muscle or organs of the fish or the seafood, and/or highly effective in eliminating microsporidia from the body of the fish or the seafood and also excellent in safety.
Type:
Application
Filed:
March 30, 2017
Publication date:
April 18, 2019
Applicants:
MARUHA NICHIRO CORPORATION, THE UNIVERSITY OF TOKYO
Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 18, 2019
Inventors:
Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
Abstract: The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Type:
Application
Filed:
December 21, 2018
Publication date:
April 18, 2019
Applicant:
Enzo Biochem, Inc.
Inventors:
Elazar Rabbani, James J. Donegan, Paul Diamond
Abstract: Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
Type:
Application
Filed:
March 15, 2017
Publication date:
April 18, 2019
Inventors:
Kevin Duane Bunker, Deborah Helen Slee, Chad Daniel Hopkins, Joseph Robert Pinchman, Mehmet Kahraman, Peter Qinhua Huang
Abstract: Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.
Type:
Application
Filed:
March 29, 2017
Publication date:
April 18, 2019
Inventors:
Jenny Jie YANG, Jian HU, Edward BROWN, Kelley MOREMEN
Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute sensorineural hearing loss or Meniere's disease with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of acute sensorineural hearing loss or Meniere's disease.
Abstract: The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
Type:
Application
Filed:
November 3, 2016
Publication date:
April 18, 2019
Inventors:
Johan FLYGARE, Lars JOHANSSON, Thomas LUNDBÄCK
Abstract: This invention relates to the use of low doses of (+)-?-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome.
Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
Abstract: This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
Type:
Application
Filed:
May 16, 2018
Publication date:
April 18, 2019
Inventors:
Zhe Li, Jason R. Harris, Kobina N. Dufu, Xin Geng, Uma Sinha